Biomerica (BMRA) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biomerica is the larger company by market cap ($8.5 million vs $2.7 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BMRA | VRAX |
|---|---|---|
| Share price | $1.85 | $1.99 |
| Market cap | $8.51M | $2.68M |
| 1-day change | -2.63% | -5.69% |
| YTD return | -24.21% | — |
| 1-year return | -32.75% | — |
| 5-year return | -95.69% | — |
| Forward P/E | 4.74 | — |
| EPS (TTM) | $-1.30 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $21.75 |
| 52-week low | $1.45 | $1.83 |
| Distance from 52-week high | -42.37% | -90.85% |
| Average volume | 70.89K | 1.77M |
| Shares outstanding | 4.60M | 1.34M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biomerica is about 3.2 times larger than Virax Biolabs Group by market value ($8.51M vs $2.68M).
BMRA vs VRAX FAQ
Which is bigger, Biomerica or Virax Biolabs Group?
Biomerica (BMRA) is larger, with a market capitalization of $8.51M compared with $2.68M for Virax Biolabs Group (VRAX).
Are Biomerica and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.